Northstrive Biosciences has received preliminary feedback from the FDA on its nonclinical studies and clinical plans for its product, EL-22, intended for use alongside GLP-1 receptor agonists in ...
Abpro Holdings Inc. and Celltrion Inc. have announced the submission of an IND application to the FDA for ABP-102 (CT-P72), a HER2 x CD3 T-cell engager. Pending clearance, a phase I trial in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results